Arcutis Biotherapeutics Announces Director Changes
Ticker: ARQT · Form: 8-K · Filed: Apr 10, 2025 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation
Related Tickers: ARQT
TL;DR
Arcutis board shakeup: Director Clapper out, Miller in. Officer pay details also filed.
AI Summary
Arcutis Biotherapeutics, Inc. announced on April 10, 2025, the departure of Director David M. M. Clapper and the election of new Director Michael J. Miller. The company also reported on compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: low — The filing primarily concerns routine board and officer changes, with no immediate financial distress or significant operational shifts indicated.
Key Players & Entities
- David M. M. Clapper (person) — Departing Director
- Michael J. Miller (person) — Newly Elected Director
- Arcutis Biotherapeutics, Inc. (company) — Registrant
FAQ
Who has departed from the Arcutis Biotherapeutics Board of Directors?
David M. M. Clapper has departed from the Board of Directors.
Who has been elected as a new Director to the Arcutis Biotherapeutics Board?
Michael J. Miller has been elected as a new Director.
What is the filing date for this Form 8-K?
The filing date is April 10, 2025.
What are the main items reported in this 8-K filing?
The filing reports on the departure of directors, election of directors, and compensatory arrangements of certain officers, as well as Regulation FD Disclosure and Financial Statements and Exhibits.
What is the state of incorporation for Arcutis Biotherapeutics, Inc.?
Arcutis Biotherapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 by David M. M. Clapper regarding Arcutis Biotherapeutics, Inc. (ARQT).